Showing 15 posts of 28 posts found.


Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

September 29, 2023
Medical Communications FDA, Karuna Therapeutics, Neurology, mental health, schizophrenia

Karuna Therapeutics has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration …


Sosei Heptares announces first subject dosed in phase 1 trial for schizophrenia therapy

July 3, 2023
Research and Development HTL'149, Neurology, Sosei Heptares, clinical trial, schizophrenia

Sosei Heptares has announced that it has dosed its first patient in its phase 1 trial evaluating HTL0048149 (HTL’149), a …

Newron announce successful results from schizophrenia study

April 1, 2021

Newron, a biopharmaceutical company focused on novel therapies, have announced the initial results from two short-term exploratory studies assessing the …


EMA receives filing for Janssen’s twice-yearly schizophrenia jab

December 7, 2020
Sales and Marketing EMA, Janssen, schizophrenia

The European Medicines Agency (EMA) has received Janssen’s Marketing Authorisation Extension for paliperidone palmitate six-monthly (PP6M), an injectable therapy administered …


Clinical trial suggests new schizophrenia drug could reduce symptoms

April 16, 2020
Business Services D2, clinical trials, schizophrenia

Results from a newly published clinical trial suggest that a new compound could treat a broad range of schizophrenia symptoms. …

FDA approves first and only transdermal patch for schizophrenia

October 16, 2019
Research and Development, Sales and Marketing FDA, Noven Pharma, Secuado, US, pharma, schizophrenia

Hisamitsu Pharmaceutical subsidiary Noven Pharmaceuticals has revealed the FDA approval of Secuado (asenapine) in adult schizophrenia patients, making it the …


Acadia’s schizophrenia drug flops in Phase 3 trial

July 23, 2019
Manufacturing and Production acadia, clinical trials, menatl health, neuroscience, pharma, phase 3, schizophrenia

Acadia Pharmaceuticals has said its schizophrenia drug Nuplazid (primavanserin) has failed to beat placebo in a Phase 3 trial. Nuplazid …


FDA delays Newron Pharmaceuticals’ trial into schizophrenia drug evenamide

May 28, 2019
Manufacturing and Production Newron Pharma, evenamide, pharma, schizophrenia

Newron Pharmaceuticals has halted a clinical trial of its schizophrenia drug evenamide after the FDA raised concerns about reports of …


Vitamin D deficiency may cause cognitive decline through weakening brain’s scaffolding

February 26, 2019
Manufacturing and Production NPP, mental health, neurology, neuroscience, schizophrenia, vitamin d

Vitamin D deficiency may weaken supportive ‘scaffolding’ in the brain thus causing neurons difficulty in maintaining connections, according to a …


Cambridgeshire and Peterborough NHS Foundation Trust launches mental health clinical trials

February 4, 2019
Sales and Marketing UK, clinical trials, clozapine, mental health, schizophrenia

The Cambridgeshire and Peterborough NHS Foundation Trust’s Windsor Research Unit is offering patients the chance to participate in clinical trials …


Commonly used heart and diabetes drugs may improve mental health, study finds

January 10, 2019
Research and Development UCL, bipolar, mental health, research, schizophrenia

Commonly used anti-cholesterol drugs, blood pressure drugs and medicines used for diabetes may improve the mental health of those with …


Otsuka scores EU schizophrenia approval, but acute myeloid leukaemia drug flops at Phase 3

August 1, 2018
Research and Development, Sales and Marketing Astex, Otsuka, Rxulti, guadecitabine, pharma, schizophrenia

It’s bittersweet news for Otsuka as it emerges that the European Commission saw fit to approve its therapy Rxulti (brexpiprazole) …


AstraZeneca jettisons schizophrenia drug for $538 million

May 8, 2018
Manufacturing and Production, Sales and Marketing AstraZeneca, Luye Pharma, Seroquel, pharma, schizophrenia

AstraZeneca has confirmed it has signed a deal to jettison its schizophrenia drug Seroquel and its extended release version Seroquel …

Avatar therapy holds potential as adjunct therapy for schizophrenia

November 24, 2017
Medical Communications biotech, drugs, pharma, pharmaceutical, schizophrenia

Experts have developed a new form of therapy for patients living with schizophrenia, by allowing those individuals to speak to …


Janssen says its Trevicta gets European regulatory approval as maintenance therapy for Schizophrenia

June 2, 2016
Medical Communications, Research and Development European Commission, Janssen, Trevicta, schizophrenia

Janssen said the European Commission has approved its Trevicta (paliperidone palmitate, a 3‑monthly injection) as maintenance treatment of schizophrenia.  Trevicta …

Latest content